impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24

 

  1. Department of Rheumatology, Toulouse University Hospital, Centre d’Investigation Clinique de Toulouse CIC1436, Inserm, Paul Sabatier University, Toulouse, France. ruyssen-witrand.a@chu-toulouse.fr
  2. CHU Toulouse, Hôpital Purpan, Virology Laboratory, Toulouse; INSERM UMR1291 - CNRS UMR5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), Toulouse, France.
  3. Clinical Research and Epidemiology Unit, CHU Montpellier, University of Montpellier, France.
  4. UA11 Institute of Epidemiology and Public Health, INSERM, University of Montpellier, France.
  5. Department of Rheumatology, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, France.
  6. Desbrest Institute of Epidemiology and Public Health (IDESP), Université de Montpellier, INSERM, Department of Rheumatology, CHU Nîmes, Montpellier, France.
  7. Service de Rhumatologie, Université de Paris, Hôpital Cochin Port Royal, AP-HP, and Unité Mixte AP-HP/Institut Pasteur, Institut Pasteur, Immunoregulation Unit, Paris, France.
  8. Department of Rheumatology, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, France.
  9. Occupational Diseases Department, Toulouse University Hospital; Inserm UMR 1295: Center for Research in Population Health (CERPOP), Department of Epidemiology and Public Health, University of Toulouse, France.
  10. Service des Maladies Infectieuses et Tropicales, CHU de Toulouse & Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Université Toulouse, France.
  11. Sorbonne University, CRSA, INSERM Department of Rheumatology, AP-HP Saint-Antoine Hospital, Paris, France.
  12. Université Côte d’Azur (UCA), Service de Rhumatologie, CHU de Nice, Hôpital Pasteur, Nice; UMR E-4320 MATOs CEA/iBEB/SBTN, Faculté de Médecine, Université Nice Sophia Antipolis, Nice, France.
  13. Department of Rheumatology, Nancy University Hospital Nancy, and IMoPA 7561 CNRS, University of Lorraine, Vandoeuvre‑Lès‑Nancy, Nancy, France.
  14. University of Lyon, INSERM U1033 LYOS and Department of Rheumatology, Groupement Hospitalier Sud, Hospice Civils de Lyon, Pierre-Bénite, France.
  15. Department of Rheumatology, CHU de Brest, and INSERM 1227 LBAI Université de Bretagne Occidentale, Centre de Référence des Maladies Auto-Immunes Rares de l'Adulte, Brest, France.
  16. Sorbonne Université, Assistance Publique Hôpitaux de Paris, Service de Rhumatologie, Groupe Hospitalier Pitié-Salpêtrière, Institut Pierre Louis d’Épidémiologie et de Santé Publique Département de Biostatistiques, INSERM UMR 1136, Paris, France.
  17. Department of Rheumatology, Hôpital Roger Salengro, University of Lille, France.
  18. Department of Rheumatology, Regional University Hospital Centre Tours, France.
  19. Bordeaux University Hospital, Department of Rheumatology, Reference Center for Rare Systemic Autoimmune and Autoinflammatory Diseases RESO, and Bordeaux University, CNRS, Immuno ConcEpT, UMR 5164, Bordeaux, France.
  20. Department of Rheumatology, CHU Clermont-Ferrand, France.
  21. Rouen University, Rouen University Hospital, Service de Rhumatologie, CIC-CRB 1404, INSERM, U1234, Rouen, France.
  22. Department of Rheumatology, Toulouse University Hospital INSERM UMR1291 - CNRS UMR5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy) and University Toulouse, France.
  23. CHU Toulouse, Hôpital Purpan, Virology Laboratory, Toulouse; INSERM UMR1291 - CNRS UMR5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), Toulouse, France.
  24. Department of Rheumatology, CHU and University of Montpellier, Phymedexp, Université de Montpellier, INSERM, CNRS, Montpellier, France.

CER17420
2024 Vol.42, N°11
PI 2141, PF 2149
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 39436731 [PubMed]

Received: 27/12/2023
Accepted : 18/03/2024
In Press: 17/10/2024
Published: 04/11/2024

Abstract

OBJECTIVES:
To compare the humoral response after a SARS-CoV-2 infection in an inflammatory rheumatic disease population with a healthy control population in a case-control study.
METHODS:
Cases: between March and September 2021, all consecutive unvaccinated patients followed for rheumatoid arthritis (RA), spondyloarthritis (SpA) or psoriatic arthritis (PsA) in 16 hospitals in France were systematically screened with a SARS-CoV-2 serological test. Patients with a positive test were included in the COVID-RIC-2 cohort. Controls: between June and July 2020, healthcare professionals working in the Toulouse University Hospital were screened with a SARS-CoV-2 serological test. Those with a positive test were included in the COVID-BIOTOUL cohort and matched to those from COVID-RIC-2 by age, sex and time-sampling on infection date. Analyses: total SARS-CoV-2 antibody titres were centrally measured and compared.
RESULTS:
95 patients from COVID-RIC-2 (mean age 49 years, 76% females, median delay of COVID infection: 149 days) including 48 RA, 33 SpA and 14 PsA were compared to 95 matched controls. Globally, there was no significant difference of SARS-CoV-2 antibody titres between both populations: 155 Binding Antibody Units (BAU) (IQR:7-376) in COVID-RIC-2 vs. 120 BAU (IQR:35-320) in COVID-BIOTOUL. There was a trend towards higher antibody titres in patients from COVID-RIC-2 with severe COVID-19 symptoms. In COVID-RIC-2, there was no impact of age, sex, time-sampling or underlying disease on antibody titres and patients taking glucocorticoids, abatacept or rituximab trended toward having lower antibody titres after COVID-19 infection.
CONCLUSIONS:
This study provides reassuring data on humoral response after COVID-19 infection in patients treated with disease-modifying anti-rheumatic drugs.

DOI: https://doi.org/10.55563/clinexprheumatol/48440j

Rheumatology Article